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Editorial
Theproblemz oftheetiology oftumors, andinparticularofcarcionoma,
has been investigatedforagreatmanzyyears, buthas notyet been solved.
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What Is a Tumor Promoter?
The concept of the initiation, promotion, and progression of
tumors as reflecting the natural history ofneoplasia has been widely
accepted and discussed for decades. The concept has been most
often applied to the characterization of chemicals and other sub-
stances that induce tumors. The experimental basis of the concept
was derived from the results of studies in which the application of
low doses of a DNA reactive (also known as genotoxic) carcinogen
did not result in the development of tumors until the animals were
treated repetitively with another non-DNA reactive (also known as
nongenotoxic) chemical that was itself known not to induce large
numbers of tumors. The first chemical has been called an initiator
and the second chemical referred to as the tumor promoter. The
experimental paradigm came to be called two-stage carcinogenesis
and became widely used to study the development of neoplasia. A
hallmark ofthe model was that the effects ofthe initiator were irre-
versible, and application of the tumor promoter could be delayed
many weeks or months. Also, the promoting substance did not
induce tumors following limited exposures. The two-stage model
has been adapted to several different tissues including the liver, thy-
roid, bladder, and, most often, the skin. In this editorial I present
my perspective on how the identification of tumor promotion
relates to the assessment ofhuman health risk from environmental
carcinogens. It is an important issue because few new chemicals are
introduced into commerce or the environment today that are tradi-
tional genotoxic carcinogens.
In the skin, the early and predominant response is the develop-
ment ofbenign squamous papillomas. In the liver, it is foci ofcells
with an altered pattern ofproliferation reflected in the loss or gain of
enzyme markers. In some cases these benign neoplasias could be
associated with the subsequent development ofmalignant or invasive
tumors such as squamous cell carcinomas ofthe skin or hepatocellu-
lar carcinomas. Further studies on the evolution ofthe malignancies
led to the concept of tumor progression wherein repetitive exposure
to a tumor promoter following initiation could result in the acquisi-
tion of independent growth potential for some cells associated with
the benign neoplasms.
Subsequent characterization of many tumor-initiating agents
showed them to be efficient mutagens in in vitro and in vivo geno-
toxicity assays. Papillomas induced by a two-stage skin protocol
were often found to have characteristic mutations in the c-Ha-ras
gene. Similar c-Ha-ras mutations were found in keratinocytes grown
in vitro that were treated with an initiator; these keratinocytes devel-
oped into papillomas when implanted onto normal skin. In other
two-stage models, e.g., rat liver, mouse bladder, thyroid, etc., such
gene-specific mutations have not been identified, but the initiating
agents are generally DNA reactive chemicals.
The role ofthe tumor-promoting agents has not been so specif-
ically defined, even in the most well-studied mouse skin model.
However, certain properties do appear to be shared by most pro-
moters and are represented by the use of receptor-mediated path-
ways of induced gene expression. Induction of a variety of
biochemical pathways linked to
the expression of individual genes
have been identified and are asso-
ciated with induced cell prolifera- _pw Xtion, exhibited as hyperplasia in
the skin, or proliferative foci in the
liveror thyroid.
Another common property is
that most tumor promoters are
non-DNA reactive. Most non-
DNA reactive substances tested in
two-stage models have shown tumor-promoting potential. Few, if
any, such chemicals have been reported to show no tumor-promot-
ing potential. In addition, few, if any, DNA reactive or genotoxic
substances are only tumor initiators. Ifapplied repetitively, initiators
have the capacity to both initiate and promote tumor development
and also to cause progression to malignancy.
This is also the phenomenon seen in conventional 2-year car-
cinogenicity bioassays in mice and rats. Long-term, repetitive expo-
sures to either DNA reactive or nonreactive substances can result in
the initiation/promotion and progression of tumors. It can further
be said that most of the agents which have shown tumor promo-
tion capability in two-stage models have induced tumors alone
when administered repetitively in conventional bioassays. The basis
for classification of a chemical as a tumor promoter is therefore
conditional and is done only within the context of a two-stage
model protocol. These facts suggest that the mechanisms by which
tumor promotion is achieved in a two-stage model are also intrinsic
to the capacity ofnon-DNA reactive substances to induce tumors in
conventional bioassays. The corollary to this is that the capacity of
DNA reactive initiators to induce tumors in conventional assays is
intrinsic to their capacity to also promote tumor development. For
the vast majority ofsubstances that are carcinogenic, repetitive expo-
sures are required. There are relatively few DNA reactive complete
carcinogens that have been shown to induce cancers following single
exposures (e.g., X rays, urethane, ethyl nitrosourea). For virtually all
other carcinogens, repetitive or prolonged exposures are necessary.
A concern regarding repetitive exposure is that for relatively
weak carcinogens it is possible that the power of the assay (i.e.,
number ofanimals at risk per dose per unit oftime) is inadequate to
show a single dose/exposure effect. However, the combined results
of over 400 bioassays conducted by the National Toxicology
Program (NTP) show that exposures to a maximum tolerated dose
(MTD) ofthe chemical for over two-thirds ofthe animal's life span
is needed for even DNA reactive agents.
If repetitive exposures are required to manifest the carcinogenic
potential ofsubstances, the distinction between tumor initiator and
tumor promoter becomes problematic. The action of the initiator
appears to potentiate the tumor induction process through the
induction of mutations in appropriate target cells, which are then
provided with a proliferative stimulus by the actions ofthe promoter.
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In conventional bioassays the capacity ofan initiator to also promote
the proliferation ofinitiated cells may be somewhat less, but it is still
effective when exposures are repeated. The non-DNA reactive car-
cinogen or promoter may, conversely, be less efficient in creating
cells that can be promoted into tumor development. Repetitive expo-
sure to a promoter alone may result in mutations via indirect oxida-
tive pathways or changes in gene regulation that provide cells with a
proliferative advantage. The initiation step in the two-stage model
thus potentiates the neoplastic process, which then develops over a
period of many weeks upon repetitive exposure to the promoter,
whereas the equivalent process in conventional bioassays requires a
period ofmanymonths oryears to develop.
The relationships described above have implications in drug
and chemical safety assessment and risk assessment. There is a well-
defined correlation between mutagenic or DNA reactive potential
and carcinogenic potential. In the NTP database approximately
70% of the mutagens have been determined to be carcinogenic.
However, even at the maximum tolerated dose, all of the sub-
stances have involved repetitive exposures, and many chemicals
demonstrated carcinogenic potential only after 2 years ofexposures
and can only be observed after a detailed postmortem histopatho-
logic examination. In addition, a large number ofboth DNA reac-
tive and nonreactive chemicals were classified as carcinogens on the
basis ofa statistically significant increase in the incidence oftumors
that have a high historical background frequency and inbred genet-
ic bias in control animals. These agents may be promoting the
development ofgenetically determined tumor cells via mechanisms
or pathways that are different from those in two-stage tumor mod-
els. The classification of a chemical which causes an increase only
in tumors that have a genetic bias in the test species is problematic
from a risk assessment viewpoint. In these cases the action of the
chemical may be to only indirectly affect the penetrance ofthe dis-
ease gene(s) and may have no consequence to other species or even
to other strains of the same species. The interpretation of such
effects as "clear evidence ofcarcinogenicity," however, makes these
chemicals equivalent to other more potent carcinogens. Further,
the presence ofa high incidence ofbackground tumors renders the
effort to define the nature of the dose-response curve (i.e., linear
vs. nonlinear) difficult and a risk assessment inherently problematic
for species inwhich such susceptibility genes are absent.
The circumstances discussed above have now prevailed for
decades and form the basis ofmost controversy in extrapolating the
results ofanimal studies to humans. Despite the capability to identify
tumor promotion potential, the data are not generally utilized in risk
assessments. Progress is dearly needed on several fronts to improve
our capacity to assess potential environmental cancer risks in
humans. Beyond the use ofthe two-stage model to identify promo-
tion activity, there is no information such as chemical structure or in
vitro effects to reliably predict potential non-DNA reactive carcino-
gens. However, if the identification of non-DNA reactive carcino-
gens also identifies tumor promotion potential, the latter can be a
surrogate. We have proposed that transgenic mouse models may be
useful in this effort. Two lines, the zetaglobin v-Ha-ras (Tg.AC) and
c-Ha-ras (Hras2) models, have been shown to possess a capability to
respond to carcinogens. Both ofthese models, and thep53 deficient
line that preferentially identifies mutagenic carcinogens, are currently
being evaluated in an international pharmaceutical collaborative pro-
ject that is being managed by the International Life Sciences Institute
(ILSI). The results of this effort, which includes other alternative
models and 20 chemicals being tested in over 30 laboratories, will
provide decisive data for the future use ofthese models. Iftrue non-
DNA reactive carcinogenic potential can be identified in transgenic
bioassays of 6-month duration, it will be possible to derive
dose-response and dose-rate data on a low to negligible background
tumor incidence. Ultimately, it will also provide data for the devel-
opment of possible structure-activity relationships for non-DNA
reactive carcinogens. These systems will also allow for a direct explo-
ration of the induced gene expression hypothesis. The explosive
development ofgene expression array technology makes it possible to
systematically assess the patterns of temporal, spatial, and dose-
dependent changes in gene expression in the tissues of mice. By
direct comparison to concurrent controls, the genes for which
induced expression is transgene dependent can be identified. It is also
possible to compare them to changes in gene expression induced in
the promotional phase of the two-stage model. Such an approach
will identify critical genes and regulatory pathways that are common
between the various models and thus identify genes whose induced
expression maybe a biomarker for non-DNA reactive carcinogens. It
is also plausible that genes whose expression is required in highly
conserved regulatory pathways for cell proliferation, differentiation,
apoptosis, or injury may be identified and tested as surrogate bio-
markers for drug and chemical safety in exposed humans. These
approaches are speculative at this time, but a better understanding of
the molecular consequences ofchemical exposure are required ifwe
are to move beyond the concepts that have guided us for the past
decades. The availability ofreliable alternative models and methods
for large-scale analysis ofgene expression mandate that we challenge
those concepts.
To succinctly restate my proposition, tumor promoters are com-
plete non-DNA reactive carcinogens that are identified in a shorter
time by the two-stage assay. Such carcinogens can also be seen in an
even shorter time using a transgenic mouse model. The mecha-
nism(s) ofcarcinogenesis in all three situations involve induced and
sustained specific gene expression as a key element. True non-DNA
reactive carcinogens must be distinguished, however, from chemi-
cals that show strain or species-specific responses in the long-term
bioassays because the latter are unlikely to represent a threat to
human health. Recent advances in biotechnology provide new tools
with which toverify this hypothesis.
Raymond Tennant
NIEHS
Research Triangle Park, North Carolina
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